-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $25

Benzinga·06/01/2026 10:17:41
Listen to the news
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $27 to $25.